Epilepsy Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana B

Epilepsy Pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analyzes DelveInsight.

Epilepsy Overview:

Epilepsy is a prevalent and serious neurological condition affecting over 50 million people globally. It is characterized by a chronic predisposition to epileptic seizures, along with associated cognitive, psychological, and social challenges. The condition exhibits a bimodal incidence pattern, with the highest risk occurring in infants and the elderly. An epileptic seizure refers to a temporary behavioral change, which may include observable signs or subjective symptoms such as loss of awareness, stiffening, jerking, a rising abdominal sensation, a burnt rubber smell, or déjà vu. These symptoms result from abnormal, excessive, or synchronized neuronal activity in the brain.

Epilepsy is a chronic, non-communicable brain disorder marked by recurrent and unpredictable seizures. A seizure is defined as a sudden change in behavior caused by a temporary disruption in the brain's electrical activity. Normally, the brain produces small electrical impulses in a systematic pattern, which are transmitted through neurons and communicated to the body via neurotransmitters. Seizures occur due to excessive electrical discharges in specific groups of brain cells.

The pathophysiology of epilepsy involves transforming a normal neural network into a hyperexcitable one. This process disrupts extracellular ion balance, alters energy metabolism, modifies receptor function, and changes neurotransmitter uptake, all contributing to the condition.

Request for a detailed insights report on Epilepsy pipeline insights @ https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Epilepsy Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Epilepsy Therapeutics Market.

Key Takeaways from the Epilepsy Pipeline Report

DelveInsight's Epilepsy pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Epilepsy treatment.
In January 2025, Alembic received FDA approval for its generic version of AbbVie's Depakote Sprinkle, divalproex sodium delayed-release capsules (125 mg). Divalproex sodium is an anti-epileptic medication used to manage epilepsy, specifically for complex partial seizures, simple and complex absence seizures, and as an adjunct therapy for multiple seizure types.
In December 2024, Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced that the FDA granted seven years of orphan drug exclusivity (ODE) to Libervant® (diazepam) Buccal Film. This treatment is designed to address acute seizure clusters or acute repetitive seizures in epilepsy patients aged 2 to 5 years, providing a novel approach to managing these critical episodes.
Key Epilepsy companies such as UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others are evaluating new drugs for Epilepsy to improve the treatment landscape.
Promising Epilepsy pipeline therapies in various stages of development include EPX-100, BMB-101, STK-001, NRTX-1001, IAMA-6, and others.

Epilepsy Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Epilepsy Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Epilepsy market.

Download our free sample page report on Epilepsy pipeline insights @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Epilepsy Emerging Drugs

EPX-100: Harmony Biosciences
BMB-101: Bright Minds Biosciences
STK-001: Stoke Therapeutics
NRTX-1001: Neurona Therapeutics
IAMA-6: IAMA Therapeutics

Epilepsy Companies

Approximately 75 key companies are actively developing therapies for epilepsy. Among them, Harmony Biosciences has an epilepsy drug candidate in the most advanced stage of development, namely Phase III.

DelveInsight's report covers around 90+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Epilepsy Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Epilepsy Therapies and Key Companies: Epilepsy Clinical Trials and advancements @ https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Epilepsy Pipeline Therapeutic Assessment
• Epilepsy Assessment by Product Type
• Epilepsy By Stage
• Epilepsy Assessment by Route of Administration
• Epilepsy Assessment by Molecule Type

Download Epilepsy Sample report to know in detail about the Epilepsy treatment market @ Epilepsy Therapeutic Assessment @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Epilepsy Current Treatment Patterns
4. Epilepsy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Epilepsy Late-Stage Products (Phase-III)
7. Epilepsy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Epilepsy Discontinued Products
13. Epilepsy Product Profiles
14. Epilepsy Key Companies
15. Epilepsy Key Products
16. Dormant and Discontinued Products
17. Epilepsy Unmet Needs
18. Epilepsy Future Perspectives
19. Epilepsy Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Epilepsy Pipeline Reports Offerings: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.